Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Clinical trial NCT04647110 · COMPLETED
Trial details
- NCT number
- NCT04647110
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-12-14
- Primary completion
- 2021-03-15
- Enrollment
- 549
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.